Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Gefitinib

FDA-approved product (tablet, oral), marketed as Gefitinib, Iressa.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Gefitinib
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Neoplasm
  • Non-small cell lung carcinoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Epidermal growth factor receptor (egfr) tyrosine kinase inhibitors
FDA pharmacologic class
Kinase Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA56.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli50.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae31.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis65.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Gefitinib in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.3 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.8 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.9 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.5 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Gefitinib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Drug-drug Interaction Study of Gefitinb on Apatinib in NSCLC Patients

    NCT04390984 · start 2020-05-26

    Registered record
    Registry ID
    NCT04390984
    Conditions
    NSCLC
    Interventions
    Apatinib Mesylate, Gefitinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Unknown
    Start
    2020-05-26
    Completion
    2021-03
    Enrolment
    22

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNSCLC
    InterventionApatinib Mesylate, Gefitinib
    PhasePhase 1
    Registry statusUnknown

  • A Study of SH-1028 Tablets Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

    NCT04239833 · start 2020-01-31

    Registered record
    Registry ID
    NCT04239833
    Conditions
    Non-Small Cell Lung Cancer
    Interventions
    SH-1028 tablets; Placebo SH-1028 tablets; Gefitinib; Placebo Gefitinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2020-01-31
    Completion
    2024-01-31
    Enrolment
    240

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-Small Cell Lung Cancer
    InterventionSH-1028 tablets; Placebo SH-1028 tablets; Gefitinib; Placebo Gefitinib
    PhasePhase 3
    Registry statusUnknown

  • Anlotinib Hydrochloride Combined With EGFR-Tyrosine Kinase Inhibitor (TKI) in Treating Advanced NSCLC Patients With Acquired Resistance to EGFR-TKI

    NCT04007835 · start 2019-07

    Registered record
    Registry ID
    NCT04007835
    Conditions
    NSCLC
    Interventions
    Anlotinib Hydrochloride
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2019-07
    Completion
    2021-12
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNSCLC
    InterventionAnlotinib Hydrochloride
    PhaseNot applicable
    Registry statusUnknown

  • Anlotinib Hydrochloride Combined With EGFR TKIs in Advanced Non-small Cell Lung Cancer

    NCT03766490 · start 2019-03-30

    Registered record
    Registry ID
    NCT03766490
    Conditions
    Non-Small-Cell Lung
    Interventions
    Anlotinib Hydrochloride; Gefitinib; Icotinib
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2019-03-30
    Completion
    2020-12-20
    Enrolment
    66

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-Small-Cell Lung
    InterventionAnlotinib Hydrochloride; Gefitinib; Icotinib
    PhaseNot applicable
    Registry statusUnknown

  • Abivertinib Maleate Versus Geifitinib in Patients With Advanced Non-small Cell Lung Cancer With Sensitive EGFR Mutation

    NCT03856697 · start 2019-03

    Registered record
    Registry ID
    NCT03856697
    Conditions
    Advanced Non-small Cell Lung Cancer
    Interventions
    Abivertinib Maleate Capsules; Placebo Gefitinib Tablets; Gefitinib Tablets; Placebo Abivertinib Maleate Capsules
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2019-03
    Completion
    2024-03
    Enrolment
    406

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Non-small Cell Lung Cancer
    InterventionAbivertinib Maleate Capsules; Placebo Gefitinib Tablets; Gefitinib Tablets; Placebo Abivertinib Maleate Capsules
    PhasePhase 3
    Registry statusUnknown

  • An Autologous NK/CIK Cell Product (PB101) in Combination With EGFR-TKI for Treating Lung Cancer

    NCT07271446 · start 2018-09-01

    Registered record
    Registry ID
    NCT07271446
    Conditions
    Non-small Cell Lung Cancer
    Interventions
    PB101 plus EGFR-TKI including gefitinib, erlotinib, afatinib, or osimertinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2018-09-01
    Completion
    2023-12-01
    Enrolment
    8

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-small Cell Lung Cancer
    InterventionPB101 plus EGFR-TKI including gefitinib, erlotinib, afatinib, or osimertinib
    PhasePhase 1
    Registry statusCompleted

  • Phase I Study of the Combination of Anlotinib With Gefitinib

    NCT03602027 · start 2018-08-01

    Registered record
    Registry ID
    NCT03602027
    Conditions
    Non-squamous Non-small Cell Lung Cancer
    Interventions
    Anlotinib; Gefitinib
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2018-08-01
    Completion
    2019-02-01
    Enrolment
    9

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-squamous Non-small Cell Lung Cancer
    InterventionAnlotinib; Gefitinib
    PhaseNot applicable
    Registry statusUnknown

  • Molecularly Target Therapy With GEMOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma

    NCT02836847 · start 2016-07

    Registered record
    Registry ID
    NCT02836847
    Conditions
    Cholangiocarcinoma of the Extrahepatic Bile Duct; Gallbladder Cancer
    Interventions
    biological test; GEMOX; Cetuximab; Trastuzumab; Gefitinib; Lapatinib; Everolimus; Sorafenib; Crizotinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2016-07
    Completion
    2020-12
    Enrolment
    152

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCholangiocarcinoma of the Extrahepatic Bile Duct; Gallbladder Cancer
    Interventionbiological test; GEMOX; Cetuximab; Trastuzumab +5 more
    PhasePhase 2
    Registry statusUnknown

  • A Study to Predict Gefitinib' s Efficacy for Lung Cancer by Plasma Free Nucleic Acids EGFR Gene Mutation Test

    NCT02738684 · start 2016-04

    Registered record
    Registry ID
    NCT02738684
    Conditions
    Lung Adenocarcinoma
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2016-04
    Completion
    2018-01
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLung Adenocarcinoma
    InterventionNot recorded
    PhaseNot recorded
    Registry statusUnknown

  • Induction Therapy With Intercalated Tyrosine Kinase Inhibitor (TKI) and Chemotherapy in NSCLC With Activating Epidermal Growth Factor Receptor (EGFR) Mutation in Stages II-IIIB

    NCT02326285 · start 2015-11

    Registered record
    Registry ID
    NCT02326285
    Conditions
    Non-squamous Non-small Cell Lung Cancer Stage II; Non-squamous Non-small Cell Lung Cancer Stage IIIA; Non-squamous Non-small Cell Lung Cancer Stage IIIB; Activating EGFR Mutation; NSCLC
    Interventions
    Gefitinib; docetaxel; cisplatin; Surgery
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Terminated
    Start
    2015-11
    Completion
    2018-01
    Enrolment
    1

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-squamous Non-small Cell Lung Cancer Stage II; Non-squamous Non-small Cell Lung Cancer Stage IIIA; Non-squamous Non-small Cell Lung Cancer Stage IIIB; Activating EGFR Mutation +1 more
    InterventionGefitinib; docetaxel; cisplatin; Surgery
    PhasePhase 2 / Phase 3
    Registry statusTerminated

  • A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY)

    NCT02411448 · start 2015-05-06

    Registered record
    Registry ID
    NCT02411448
    Conditions
    Metastatic Non-Small Cell Lung Cancer
    Interventions
    Ramucirumab; Placebo; Erlotinib; Gefitinib; Osimertinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2015-05-06
    Completion
    2026-12
    Enrolment
    545

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Non-Small Cell Lung Cancer
    InterventionRamucirumab; Placebo; Erlotinib; Gefitinib +1 more
    PhasePhase 3
    Registry statusActive not recruiting

  • A Phase I Study of Safety and Pharmacokinetics of Volitinib in Combination With Gefitinib in EGFR(+) NSCLC

    NCT02374645 · start 2015-04

    Registered record
    Registry ID
    NCT02374645
    Conditions
    Non-Small Cell Lung Cancer
    Interventions
    Volitinib; gefitinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2015-04
    Completion
    2018-09-14
    Enrolment
    64

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-Small Cell Lung Cancer
    InterventionVolitinib; gefitinib
    PhasePhase 1
    Registry statusCompleted

  • Pemetrexed Combined With Synchronous Gefitinib as Adjuvent Therapy in Patient With EGFR Mutant Lung Adenocarcinoma

    NCT02518802 · start 2015-01

    Registered record
    Registry ID
    NCT02518802
    Conditions
    Lung Neoplasms
    Interventions
    Gefitinib; Pemetrexed
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2015-01
    Completion
    2020-01
    Enrolment
    220

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLung Neoplasms
    InterventionGefitinib; Pemetrexed
    PhasePhase 3
    Registry statusUnknown

  • Combination of Chemotherapy and Gefitinib as First-line Treatment

    NCT02148380 · start 2014-05

    Registered record
    Registry ID
    NCT02148380
    Conditions
    Non-Small-Cell Lung Cancer
    Interventions
    pemetrexed plus carboplatin; gefitinib
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2014-05
    Completion
    2015-12
    Enrolment
    121

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-Small-Cell Lung Cancer
    Interventionpemetrexed plus carboplatin; gefitinib
    PhaseNot applicable
    Registry statusCompleted

  • Third-line Treatment of Gefitinib in NSCLC Patients

    NCT01933347 · start 2014-04-07

    Registered record
    Registry ID
    NCT01933347
    Conditions
    Non Small Cell Lung Cancer
    Interventions
    Gefitinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2014-04-07
    Completion
    2018-04-10
    Enrolment
    46

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon Small Cell Lung Cancer
    InterventionGefitinib
    PhasePhase 2
    Registry statusCompleted